Advertisement

Bone Marrow Transplantation Extends Its Scope

  • Fermín M. Sánchez-Guijo
  • Alberto Orfao
  • María Consuelo del CañizoEmail author
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 741)

Abstract

The term hematopoietic stem cell transplantation (HSCT) has completely replaced the most widespread bone marrow transplantation (BMT). This semantic change is based on the fact that not only hematopoietic stem cells with capacity for regenerating haematopoiesis and the immune system of the recipient are located in the BM. It was later observed that is possible to mobilise these cells into the peripheral blood, with the aid of certain cytokines, and then collect them through the process of aphaeresis. Moreover, hematopoietic stem cells from umbilical cord blood have been used successfully, and their use in on the increase. The main objectives of HSCT are, first, to substitute a defective haematopoietic system for a healthy one and, secondly, to allow the use of chemo and/or radiotherapy treatment at what would otherwise be supralethal doses, re-establishing haematopoiesis through the administration of haematopoietic progenitor cells. The complications of HSCT tend to be the result of the various factors including toxicity, release of certain cytokine, immunological processes associated with allo-HSCT (especially GVHD) and the effect of immunosuppressive drugs, as we discussed below.

Keywords

Stem Cell Mesenchymal Stem Cell Hematopoietic Stem Cell Transplantation Umbilical Cord Blood Endothelial Progenitor Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    McCulloch EA, Till JE. Perspectives on the properties of stem cells. Nat Med 2005; 11:1026–1028.PubMedCrossRefGoogle Scholar
  2. 2.
    Friedenstein AJ, Chailakhjan RK, Lalykina KS. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet 1970; 3:393–403.PubMedGoogle Scholar
  3. 3.
    Jiang Y, Jahagirdar BN, Reinhardt RL et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002; 418:41–49.PubMedCrossRefGoogle Scholar
  4. 4.
    Sanchez-Guijo FM, Sanchez-Abarca LI, Villaron E et al. Postrasplant hematopoiesis in patients undergoing sibling allo-SCT reflects that of their respective donors although with a lower functional capability. Exp Hematol 2005; 33:935–943.PubMedCrossRefGoogle Scholar
  5. 5.
    Horwitz EM, Le Blanc K, Dominici M et al. Clarification of the nomenclature for MSC: The international society for cellular therapy position statement. Cytotherapy 2005; 7:393–395.PubMedCrossRefGoogle Scholar
  6. 6.
    Dominici M, Le Blanc K, Mueller I et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy 2006; 8:315–317.PubMedCrossRefGoogle Scholar
  7. 7.
    Giordano A, Galderisi U, Marino IR. From the laboratory bench to the patient’s bedside: An update on clinical trials with mesenchymal stem cells. J Cell Physiol 2007; 211:27–35.PubMedCrossRefGoogle Scholar
  8. 8.
    Park C, Ma YD, Choi K. Evidence for the hemangioblast. Exp Hematol 2005; 33:965–970.PubMedCrossRefGoogle Scholar
  9. 9.
    Grant MB, May WS, Caballero S et al. Adult hematopoietic stem cells provide functional hemangioblast activity during retinal neovascularisation. Nat Med 2002; 8:607–612.PubMedCrossRefGoogle Scholar
  10. 10.
    Asahara T, Murohara T, Sullivan A et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275:964–967.PubMedCrossRefGoogle Scholar
  11. 11.
    Peichev M, Naiyer AJ, Pereira D et al. Expression of VEGFR-2 and AC133 by circulating human CD34+ cells identifies a population of functional endothelial precursors. Blood 2000; 95:952–958.PubMedGoogle Scholar
  12. 12.
    López-Holgado N, Alberca M, Sánchez-Guijo F et al. Short-term endothelial progenitor cell colonies are composed of monocytes and do not acquire endothelial markers. Cytotherapy 2007; 9:14–22.PubMedCrossRefGoogle Scholar
  13. 13.
    Werner N, Kosiol S, Schiegl T et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005; 353:999–1007.PubMedCrossRefGoogle Scholar
  14. 14.
    Sanchez-Guijo FM, Oterino E, Alberca M et al. Trasplante de células progenitoras endoteliales. Methods Find Exp Clin Pharmacol 2007; 29 (Supl 1):11–15.Google Scholar
  15. 15.
    Apperley J, Carreras E, Gluckman E et al. Haematopoietic stem cell transplantation (EBMT Handbook) 5th edition. Genova, Forum Service Editore, 2008.Google Scholar
  16. 16.
    Perez-Simon JA, Caballero D, San Miguel JF. Trasplante de progenitores hematopoyéticos. En: Trasplante de óorganos y células: dimensiones éticas regulatorias. J Rodes Teixidor, ed. Fundacián BBVA, Bilbao, 2006.Google Scholar
  17. 17.
    Urbano-Ispizua A, Rozman C. Trasplante de progenitores hematopoyéticos. En:Hematología Clínica. J Sans-Sabrafen, C Besses Raebel, JL Vives-Corrons eds., 5a Edición. Elsevier, Madrid, 2006.Google Scholar
  18. 20.
    Ljungman P, Urbano-Ispizua A, Cavazzana-Calvo M et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: Definitions and current practice in Europe. Bone Marrow Transplant 2006; 37:439–449.PubMedCrossRefGoogle Scholar
  19. 21.
    Walter EA, Greenberg PD, Gilbert MJ et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995; 333:1038–1044.PubMedCrossRefGoogle Scholar
  20. 22.
    Einsele H, Kapp M, Grigoleit GU. CMV-specific T-cell Therapy. Blood Cells Mol Dis 2008; 40:71–75.PubMedCrossRefGoogle Scholar
  21. 23.
    Koé ON, Gerson SL, Cooper BW et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 2000; 18:307–316.Google Scholar
  22. 24.
    Le Blanc K, Samuelsson H, Gustafsson W et al. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia 2007; 21:1733–1738.PubMedCrossRefGoogle Scholar
  23. 25.
    Le Blanc K, Frassoni S, Ball L et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: A phase II study. Lancet 2008; 371:1579–1586.PubMedCrossRefGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2012

Authors and Affiliations

  • Fermín M. Sánchez-Guijo
    • 1
    • 3
  • Alberto Orfao
    • 2
  • María Consuelo del Cañizo
    • 1
    • 3
    Email author
  1. 1.Haematology DepartmentUniversity Hospital of SalamancaSalamancaSpain
  2. 2.General Cytometry ServiceUniversity of SalamancaSalamancaSpain
  3. 3.Regenerative Medicine and Cell Therapy Network Centre of Castilla y Leon (SACYL-ISCIII)SalamancaSpain

Personalised recommendations